/PRNewswire/ The global ursodeoxycholic acid market size is estimated to grow by USD 358.41 million from 2023-2027, according to Technavio. The market is.
Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156 14 million by 2030 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
1. In this randomized controlled trial, among patients with primary biliary cholangitis (PBC) who had had inadequate response to ursodeoxycholic acid, seladelpar was superior to placebo in achieving biochemical response and symptomatic management. 2. Seladelpar had an acceptable safety profile, with similar rates of adverse events to a placebo. Evidence Rating Level: 1 (Excellent) Study
Results from the phase 3 trial showed seladelpar elicited biochemical response, normalized alkaline phosphatase, and reduced pruritus at a greater rate than placebo.
Award Winning Global Entrepreneur and Chief of Arch Pharma Labs Dr Ajit Kamath Accorded Honorary Doctorate in Health Administration aninews.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aninews.in Daily Mail and Mail on Sunday newspapers.